Jana Hof

1.7k total citations
18 papers, 999 citations indexed

About

Jana Hof is a scholar working on Public Health, Environmental and Occupational Health, Molecular Biology and Hematology. According to data from OpenAlex, Jana Hof has authored 18 papers receiving a total of 999 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Public Health, Environmental and Occupational Health, 9 papers in Molecular Biology and 5 papers in Hematology. Recurrent topics in Jana Hof's work include Acute Lymphoblastic Leukemia research (11 papers), Acute Myeloid Leukemia Research (4 papers) and Cancer therapeutics and mechanisms (4 papers). Jana Hof is often cited by papers focused on Acute Lymphoblastic Leukemia research (11 papers), Acute Myeloid Leukemia Research (4 papers) and Cancer therapeutics and mechanisms (4 papers). Jana Hof collaborates with scholars based in Germany, United States and United Kingdom. Jana Hof's co-authors include Renate Kirschner‐Schwabe, Cornelia Eckert, Arend von Stackelberg, Stefanie Groeneveld‐Krentz, Shabnam Shalapour, Karl Seeger, Adolfo A. Ferrando, Hossein Khiabanian, Scott A. Snyder and Daniel A. Wespe and has published in prestigious journals such as Journal of the American Chemical Society, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Jana Hof

17 papers receiving 987 citations

Peers

Jana Hof

PHEOH

HEMAT

ONCOL

PPCH

Nicoletta Colombo Italy

A. H. Loonen Netherlands

G R Westerhof Netherlands

Rita Azevedo Portugal

R Schlossman United States

Simon Bomken United Kingdom

W. Plunkett United States

R N Sridhara United States

D. M. Moccio United States

Joanna Opalinska United States

Nicoletta Colombo Italy

Jana Hof

162 ×0.3

PHEOH

369 ×0.9

HEMAT

258 ×0.8

238 ×0.9

ONCOL

22 ×0.1

PPCH

Citations per year, relative to Jana Hof Jana Hof (= 1×) peers Nicoletta Colombo

Countries citing papers authored by Jana Hof

Since Specialization

Citations

This map shows the geographic impact of Jana Hof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jana Hof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jana Hof more than expected).

Fields of papers citing papers by Jana Hof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jana Hof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jana Hof. The network helps show where Jana Hof may publish in the future.

Co-authorship network of co-authors of Jana Hof

This figure shows the co-authorship network connecting the top 25 collaborators of Jana Hof. A scholar is included among the top collaborators of Jana Hof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jana Hof. Jana Hof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Hof, Jana, Stefanie Groeneveld‐Krentz, Annabell Szymansky, et al.. (2020). Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia. Blood. 135(12). 921–933. 17 indexed citations

Groeneveld‐Krentz, Stefanie, M. Schroeder, Michael J. Reiter, et al.. (2019). Aneuploidy in children with relapsed B‐cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse. British Journal of Haematology. 185(2). 266–283. 16 indexed citations

Richter‐Pechańska, Paulina, Joachim B. Kunz, Jana Hof, et al.. (2017). Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. Blood Cancer Journal. 7(2). e523–e523. 65 indexed citations

Hof, Jana, et al.. (2016). Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. British journal of surgery. 103(8). 1055–1062. 74 indexed citations

Irving, Julie, Elizabeth Matheson, Lynne Minto, et al.. (2014). Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 124(23). 3420–3430. 163 indexed citations

Hof, Jana, Annabell Szymansky, Arend von Stackelberg, Cornelia Eckert, & Renate Kirschner‐Schwabe. (2014). Clinical Significance of NT5C2 Mutations in Children with First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia. Blood. 124(21). 3789–3789.

Bastian, Lorenz, Jana Hof, Iduna Fichtner, et al.. (2013). Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB. Clinical Cancer Research. 19(6). 1445–1457. 36 indexed citations

Tzoneva, Gannie, Arianne Pérez-García, Zachary Carpenter, et al.. (2013). Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Medicine. 19(3). 368–371. 221 indexed citations

Irving, Julie, Elizabeth Matheson, Lynne Minto, et al.. (2013). RAS Pathway Mutations Are Highly Prevalent In Relapsed Childhood Acute Lymphoblastic Leukaemia, Are Frequently Relapse-Drivers and Confer Sensitivity To MEK Inhibition. Blood. 122(21). 823–823. 2 indexed citations

10.

Hof, Jana, Petra Dörge, Claudio Lottaz, et al.. (2012). Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia. 27(2). 295–304. 58 indexed citations

11.

Shalapour, Shabnam, Jana Hof, Renate Kirschner‐Schwabe, et al.. (2011). High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica. 96(11). 1627–1635. 56 indexed citations

12.

Snyder, Scott A., Daniel A. Wespe, & Jana Hof. (2011). A Concise, Stereocontrolled Total Synthesis of Rippertenol. Journal of the American Chemical Society. 133(23). 8850–8853. 41 indexed citations

13.

Hof, Jana, Stefanie Groeneveld‐Krentz, Gabriele Körner, et al.. (2011). Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 29(23). 3185–3193. 133 indexed citations

14.

Schuster, Heiko, Birgit Krewer, Jana Hof, et al.. (2010). Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity. Organic & Biomolecular Chemistry. 8(8). 1833–1833. 25 indexed citations

15.

Stritzker, Jochen, Ulrike Donat, Jana Hof, et al.. (2010). Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA. Cancer Gene Therapy. 18(1). 42–52. 27 indexed citations

16.

Tietze, Lutz F., Frank Behrendt, Felix Major, Birgit Krewer, & Jana Hof. (2010). Synthesis of Fluorescence‐Labelled Glycosidic Prodrugs Based on the Cytotoxic Antibiotic Duocarmycin. European Journal of Organic Chemistry. 2010(36). 6909–6921. 11 indexed citations

17.

Tietze, Lutz F., Birgit Krewer, Jana Hof, Holm Frauendorf, & Ingrid Schuberth. (2009). Determination of the Biological Activity and Structure Activity Relationships of Drugs Based on the Highly Cytotoxic Duocarmycins and CC-1065. Toxins. 1(2). 134–150. 17 indexed citations

18.

Keipert, Susanne, et al.. (2007). Dissociation of obesity and insulin resistance in transgenic mice with skeletal muscle expression of uncoupling protein 1. Physiological Genomics. 32(3). 352–359. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact